-
Sarepta won’t reopen enrollment in Duchenne gene therapy trial
Sarepta Therapeutics will not reopen enrollment in a global clinical trial testing its gene therapy Elevidys (delandistrogene moxeparvovec-rokl) in boys and men with Duchenne muscular dystrophy (DMD), the company announced in a community letter. The Phase 3 trial, called ENVISION (NCT05881408), was designed to assess Elevidys’ safety and effectiveness in late-ambulatory patients (those who can…
-
Advancing the Science of Dystrophin Measurement: PPMD Hosts 2026 Dystrophin Expression Workshop
On November 12–13, PPMD convened scientists, clinicians, industry experts, caregivers, and representatives from the Food and Drug Administration (FDA), and the Centers for Disease Control and Prevention (CDC) for the 2026 Dystrophin Expression Workshop: Harmonization of Methodologies and Communication of Readouts in Silver Spring, Maryland. The two-day workshop focused on an increasingly important question for…








